Evidence related to body weight reduction, BMI improvement, waist circumference, and body composition changes.
Build your Evidence Workspace
Save evidence about the topics you care about.
144
Studies
100
Evidence Pairs
Extensive Research
Evidence Base: 71/100
Evidence Intelligence™
Evidence Summary
A structured summary of where the evidence is strongest, mixed, or still emerging.
Executive Summary
Weight Loss evidence appears to center on Tirzepatide.
Among 144 indexed studies and 63 interventions, the strongest signals are summarized from the available evidence. Semaglutide has been studied often, while Tirzepatide appears to have stronger current evidence signals.
Evidence is consistently positive across multiple studies.
Some evidence is positive, but results are not consistent across all studies.
Early findings are encouraging, but stronger trials are needed.
Caution
This summary reflects the currently indexed evidence and should not be interpreted as treatment advice.
Freshness
Latest indexed evidence: May 2026
Key Finding
Evidence is consistently positive across multiple studies.
Interventions with strongest consistent evidence
Strongest consistent evidence
Why it matters
Consistent positive findings are easier to interpret than isolated or mixed results.
Interpretation
Tirzepatide appears to have a consistent beneficial signal in the indexed evidence.
Time-Restricted Eating (TRE), Semaglutide, and Lifestyle intervention for prediabetes are among the most studied approaches for Weight Loss.
Semaglutide, Lifestyle intervention for prediabetes, and Empagliflozin are among the best-supported options in the available evidence across 144 studies.
The evidence includes both beneficial and harmful or worsening results.
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
Consistency cannot yet be determined.
Applicability
Population details were available for 3 of 144 supporting studies. Reported populations varied; examples included Participants had longstanding T2D (mean 11.2 years) with inadequate glycemic control (mean HbA1c 7.82%) despite stable GLP-1 RA therapy (dulaglutide) for ≥6 months. Baseline characteristics were balanced between... and 78-year-old man with 40-year T2D history, 31 years insulin-dependent, sarcopenic obesity, extensive cardiovascular disease history, moderate glycemic control (HbA1c 7.0%).
Does Time-Restricted Eating (TRE) improve weight loss?
intervention effectiveness
Strong Evidence
Time-Restricted Eating (TRE) appears to improve Body weight.
ConsistencyScore™: Results are consistent across studies.
Why this answer: This answer is based on 59 supporting studies with consistent results and a positive effect signal.
Applicability
Population details were available for 3 of 59 supporting studies. Reported populations varied; examples included Participants had longstanding T2D (mean 11.2 years) with inadequate glycemic control (mean HbA1c 7.82%) despite stable GLP-1 RA therapy (dulaglutide) for ≥6 months. Baseline characteristics were balanced between... and 78-year-old man with 40-year T2D history, 31 years insulin-dependent, sarcopenic obesity, extensive cardiovascular disease history, moderate glycemic control (HbA1c 7.0%).
What has the strongest evidence for weight loss?
evidence strength
Strong Evidence
Semaglutide, Lifestyle intervention for prediabetes, and Empagliflozin have the strongest available evidence signals in this evidence set.
ConsistencyScore™: Results are consistent across studies.
Why this answer: This answer is based on 37 supporting studies with consistent results and a positive effect signal.
Applicability
Population details were available for 1 of 37 supporting studies: Participants had longstanding T2D (mean 11.2 years) with inadequate glycemic control (mean HbA1c 7.82%) despite stable GLP-1 RA therapy (dulaglutide) for ≥6 months. Baseline characteristics were balanced between....
Evidence summary for AI and search
Among 144 indexed studies and 63 interventions, the strongest signals are summarized from the available evidence. Semaglutide has been studied often, while Tirzepatide appears to have stronger current evidence signals.
Evidence is consistently positive across multiple studies.
Some evidence is positive, but results are not consistent across all studies.
Early findings are encouraging, but stronger trials are needed.
Evidence Relationships
Explore the intervention-outcome relationships with the strongest supporting evidence for Weight Loss.
19 strong relationships, ranked by available evidence
